EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis

Melissa Kartawinata, Wei-Yu Lin, Beth Jebson, Kathryn O'Brien, Elizabeth Ralph, Emma Welsh, Restuadi Restuadi, Elizabeth C Rosser, Claire T Deakin, Lucy R Wedderburn, Chris Wallace, CLUSTER Consortium

Annals of the Rheumatic Diseases · 2025-08 · 84 (8) · 1412-1424

DOI: 10.1016/j.ard.2025.03.007 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-08. Verfasst von Melissa Kartawinata und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity and Inflammation Research and Teaching Department, University College London (UCL) Great Ormond Street Institute of Child Health,…. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Juvenile, Antirheumatic Agents, Interferons. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kennedy Trust for Rheumatology Research, UK Research and Innovation Medical Research Council, NIHR Cambridge Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To identify and validate gene expression biomarkers of response to methotrexate (MTX) treatment in peripheral blood of children with juvenile idiopathic arthritis (JIA) measured before starting MTX treatment. METHODS: RNA sequencing was performed on sorted CD4+, CD8+, CD14+, and CD19+ cells, as well as peripheral blood mononuclear cells (PBMC) taken pre-treatment in a discovery cohort (n = 97) and 2 validation cohorts (n = 26 and n = 47, respectively) of patients with non-systemic JIA. Clinical data were recorded at baseline (timepoint 1) prior to treatment and 6 months (timepoint 2) of MTX treatment. Analysis tested the association of gene expression in specific cell types with treatment response using limma-voom, gene set enrichment analysis, and a novel 51-gene score against response to treatment. Parallel analysis, also using pre-treatment gene expression data, was performed in adult rheumatoid arthritis (RA) data (n = 240). RESULTS: In patients with JIA, the baseline expression of genes driven by interferon (IFN) alpha (type-I) or gamma (type-II) was associated with response to treatment at 6 months in 3 independent JIA cohorts. The direction of the association indicated that children with higher baseline expression of IFN-stimulated genes prior to MTX were more likely to be good responders. Comparison with adult RA indicated differences between PBMC and whole blood gene expression associations with response. CONCLUSIONS: In children with JIA, a high IFN-driven gene signature is associated with a better response to MTX than those with a low IFN-driven gene signature. These data could pave the way to clinically validated tools to identify those most likely to require medications in addition to MTX to control inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateArthritis, JuvenileAntirheumatic AgentsInterferonsHumansChildMaleFemaleAdolescentTreatment OutcomeChild, PreschoolTranscriptomeLeukocytes, MononuclearGene Expression ProfilingBiomarkersInterferon-gamma

Substanzen

MethotrexateAntirheumatic AgentsInterferonsBiomarkersInterferon-gamma

Autor:innen und Institutionen

  • Infection, Immunity and Inflammation Research and Teaching Department, University College London (UCL) Great Ormond Street Institute of Child Health, London, UK; National Institute for Health and Care Research (NIHR) Bi…
  • Medical Research Council (MRC) Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • Centre for Adolescent Rheumatology Versus Arthritis at University College London, University College London Hospital and Great Ormond Street Hospital, London, UK; University College London Division of Medicine, UCL, Lon…
  • Medical Research Council (MRC) Biostatistics Unit, University of Cambridge, Cambridge, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK; Department of Medi…

Förderung

  • Kennedy Trust for Rheumatology Research
  • UK Research and Innovation Medical Research Council
  • NIHR Cambridge Biomedical Research Centre
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Sparks
  • Wellcome Trust
  • NIHR Great Ormond Street Hospital Biomedical Research Centre
  • Great Ormond Street Hospital Children's Charity

Zitieren

APA

Kartawinata, M., Lin, W. Y., Jebson, B., O'Brien, K., Ralph, E., Welsh, E., Restuadi, R., Rosser, E. C., Deakin, C. T., Wedderburn, L. R., Wallace, C., & CLUSTER Consortium (2025). Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 84(8), 1412-1424. https://doi.org/10.1016/j.ard.2025.03.007

Vancouver

Kartawinata M, Lin WY, Jebson B, O'Brien K, Ralph E, Welsh E, et al. Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 2025;84(8):1412-1424. doi:10.1016/j.ard.2025.03.007

BibTeX
@article{Kartawinata2025,
  author = {Kartawinata, Melissa and Lin, Wei-Yu and Jebson, Beth and O'Brien, Kathryn and Ralph, Elizabeth and Welsh, Emma and Restuadi, Restuadi and Rosser, Elizabeth C and Deakin, Claire T and Wedderburn, Lucy R and Wallace, Chris and CLUSTER Consortium, CLUSTER Consortium},
  title = {Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {8},
  pages = {1412--1424},
  doi = {10.1016/j.ard.2025.03.007}
}
Kostenlos starten →